Several lines of evidence indicate that Chagas disease (American Trypanosomiasis) is now present in North America. A recent multi-center study has shown that 1 in 700 Hispanic blood donors from USA are infected by Trypanosoma cruzi, the etiological agent of Chagas disease (1) . Another study has found that 1 in 300 donors from California (2) may be at risk for T. cruzi. Three cases of transfusional Chagas disease have been reported in North America (3) (4) (5) and there have been recent reports of immigrants in the chronic phase of Chagas disease (6, 7) , Chagas disease is a chronic multisystemic disease caused by the flagellate Trypanosoma cruzi, whose natural vector is a reduviid bug (kissing bug) widely spread from Utah (USA) to Patagonia (Argentina). After a blood meal the bug defecates, leaving many infective trypomastigotes in the feces which may enter the bloodstream by local scratching or direct contact in the mucosa. After an acute phase (usually in children), the disease subsides into either an indeterminate (asymptomatic) or a chronic phase affecting mainly the cardiac and gastrointestinal system. Years or decades may elapse between the acute phase and the onset of symptoms. Besides transmission by insects, Chagas disease may also be conveyed by transfusion of contaminated blood, organ donation, transplacentally, by breast feeding, or by laboratory manipulation of Trypanosoma cruzi (8, 9) .
Until recently, Chagas disease was limited to poor rural areas of Latin America or to major cities where immigration had occurred. In the last decade many immigrants came to North America, where a few autochthonos cases had been previously described (10) (11) (12) (13) . Currently an estimated 3 million Latin-American immigrants are now living in USA and 100,000 to 150,000 might be infected. Other developed countries are now also being targets of immigration, mainly France, UK, Spain, Italy and Portugal in Europe (with approximately 300,000 immigrants), Japan (at least 150,000 Brazilians immigrated in the last decade) or Australia (with 80,000 Latin Americans in the last 30 years) (8) .
Since acute cases of Chagas disease are seen mainly during childhood, one would expect most of these infected immigrants to be either in the indeterminate or in the chronic phase. A lack of familiarity with this disease among physicians from developed countries had led to several such patients being misdiagnosed. A recent study in the USA (14) showed that 72% of patients had been treated as having other cardiomyopathies for up to nine years before Chagas disease was considered.
With regard to transfusional Chagas disease (TxCO), in which some 20% of acute cases are asymptomatic, fever (the main symptom of TxCO in the acute phase) might easily be attributed to other causes. Only in a few patients, usually in immunosuppresed, are overt symptoms present. This might explain the low number of TxCO detected in North America, with 2 cases in USA and one in Canada (a fourth case is suspected in USA, but no donor could be linked yet). Little is known about the recipients of donors found to be infected in these countries. The study of Kerndt et al (15) , showed no infection in one recipient and the other one could not be traced, whereas Pan et al (1) did not evaluate their recipients. It is very likely that other infected donors are currently donating blood in North America.
Thus Chagas disease is clearly no longer an exclusively Latin American problem (16) . If no preventive measures are taken, it might become another problem in Transfusion Medicine, though in a lesser importance that AI OS or Hepatitis C.
Serological screening tests have been available and led to a dramatic reduction in the number of TxCO cases in Latin America. There are some problems, however with this procedure. Importantly, false positive results may occur because the tests cross-react with other agents such as Leishmania, T. rangeli (a nonpathogenic trypanosomatid), and fungi. Moreover, the positive predictive value of a given test is quite low in a population of minute prevalence of infection, such as in North American donors. Although it should not matter greatly if a few false positive units of blood would have to be discarded there will be considerable problems on how to evaluate clinically and counsel these donors..Several laboratories are working on developing rapid, reliable and cheap confimatory tests, but only xenodiagnosis, xenoculture or hemoculture are considered efficient so far, despite its low sensitivity in chronic cases (30 to 50%). Alternative tests using synthetic peptides, recombinant antigens, or PCR have been developed, but have not proved to be useful on a large scale as yet (8) .
Another pitfall is that of false negative results. Since T. cruzi is a highly complex agent, a different immune response is observed according to the recipient's immune status or the infective strain. As no single test can detect all infected samples, at least two different methods should be used for screening blood donors. None have currently been licensed by the FDA; and although one test is currently under evaluation, it will not guarantee that all infected donors would be detected. Furthermore, as other tests become available in USA, the chances of false positive results will undoubtedly increase. Pre-donation questionnaires should detect high risk donors (2, 15) , but would not be as safe as adequate screening methods.
These problems pose a major dilemma: should developed countries, especially those in North America, screen donors routinely and accept the false positive results or should screening be restricted to high risk groups such as Latin American immigrants? What will happen if screening is adopted only in certain geographic regions and cases of TxCD are observed in the other areas where screening is not done? Should one concentrate efforts in certain places, such as California and New York, where the greater number of immigrants are found, and leave the rest of USA and Canada relying only upon predonation questionnaries? It is ethical not to screen potentially infected blood donors and put recipients at a risk that could easily be avoided? Is it necessary to wait for better tests or act immediately? Another problem is that even if TxCD could be effectively prevented in North America, a great number of infected people will still remain living there, some of them (approximately 30%), with cardiac or gastrointestinal symptoms. Even if no further immigration occurs, one can expect that 30,000 to 45,000 persons will have symptoms, needing some medical support 118 during their lifetime. In addition, these infected people may perpetuate Chagas disease by congenital transmission (17, 18) . Finally, if the complete control and eradication in the whole American Continent, is achieved, Trypanosoma cruzi will still be present in animal reservoirs, where more than 150 different species have been found infected in nature; they can easily infect humans again once migration, geographical, ecological, or poverty effects act upon the human population of America.
There are no complete answers at the moment, and further epidemiological studies are necessary to validate or refute some of the aforementioned assumptions. However, those who know only the present, are prone to repeat mistakes that have happened elsewhere in the past.
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